Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-CYC065 in Healthy Male Subjects
NCT05817890Phase 1Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Mar 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fadraciclib in solid tumor (advanced stage) and hematologic malignancy, sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoints: The routes, rates of elimination, and mass balance, Area Under the Curve for CYC065 in plasma and 3 more. Started Mar 2023; status: completed.
02
Drugs
fadraciclib
03
Conditions
solid tumor (advanced stage)hematologic malignancy
Beyond the preview
Go deeper on NCT05817890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817890.